Therapeutic Antibodies – News and Features

Evotec will use its medicinal and computational chemistry expertise to develop potent inhibitors for IL-6 using Interprotein’s number of hit molecules based on in-silico drug design.

The Oxford-based biotechnology company intends to be a leader in the development of personalised medicines for the treatment of cancer.

AstraZeneca will pay a total of up to $120 million over six years and will conduct the work at Cambridge Antibody Technology.

Both the companies will jointly screen ADC products to an initial target, co-fund all preclinical and clinical development.

The MorphoSys extends collaboration up to 2011 to use HuCAL Gold human combinatory antibody library to generate therapeutic antibodies.

MorphoSys will optimize the antibody in accordance with the requirements of the partner and will receive additional research payments.

Companies intend to use Medarex's UltiMAb Human Antibody Development System® to generate fully human antibodies.

Companies collaborate to characterize favorable interactions of Lpath's Anti-S1P therapeutic antibody with its target.

Companies announce agreement for discovery of therapeutic antibodies.

Analysis of breast-cancer gene role offers promising target for drugs to stop or slow progression of the disease.